Crinetics (CRNX) announced the submission of a marketing authorization application to Brazil’s National Health Surveillance Agency, or ANVISA, for Palsonify, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Advances Atumelnant: Phase 1 Study Completion Sets Up Next Clinical Catalyst for CRNX
- Crinetics Pharma Earnings Call: Launch, Pipeline, Runway
- Crinetics price target lowered to $96 from $105 at Citizens
- Crinetics price target lowered to $83 from $84 at Stifel
- Crinetics reports Q4 EPS ($1.29), consensus ($1.37)